Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
about
P1343
Serological diagnosis of Epstein-Barr virus infection: Problems and solutionsEpstein-Barr virus primes human polymorphonuclear leucocytes for the biosynthesis of leukotriene B4Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.Identification and characterization of Kaposi's sarcoma-associated herpesvirus K8.1 virion glycoproteinEpstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptorEpstein-Barr virus associated graft failure following heart/lung transplantation.Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infectEpstein-Barr virus recombinant lacking expression of glycoprotein gp150 infects B cells normally but is enhanced for infection of epithelial cells.Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells.Epstein-Barr virus that lacks glycoprotein gN is impaired in assembly and infectionEpstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosisAntibody evasion by a gammaherpesvirus O-glycan shieldThe immunology of Epstein-Barr virus infectionPurified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells.Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayEpstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.Varicella-zoster virus as a live vector for the expression of foreign genes.Reactivation of persistent Epstein-Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface.Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 moleculeEpithelial cell polarization is a determinant in the infectious outcome of immunoglobulin A-mediated entry by Epstein-Barr virus.Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes.Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell DysfunctionEpstein-barr virus: environmental trigger of multiple sclerosis?The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody.Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.Monoclonal antibody against a Burkitt lymphoma-associated antigen.Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivityEpstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus MacaquesRational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteEpstein-Barr virus glycoprotein gM can interact with the cellular protein p32 and knockdown of p32 impairs virus.The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110
P2860
Q26829346-46A64DFB-2E71-4B4F-8C28-D5EF98499735Q28365981-9E611675-55A0-410F-955D-FDB83115EE7FQ33605234-AA9223D4-2AA5-461F-90E2-9C2AE752232BQ33641311-60C04BAF-B7E2-4199-B601-8D876BFF169EQ33682618-87513442-59C9-4472-95A5-6AA0A6988479Q33775557-01B06D82-97E2-4E01-A0FF-256A7CF0015EQ33781911-26B3A3EF-9FFB-425A-BA4F-A41C154B5F9EQ33784012-0C29175A-9683-4A17-A1F8-82988B7F1501Q33807504-2E319986-D4AB-4048-9540-B7516B1C37D3Q33826978-C49E3F71-9B5F-4E41-B1FD-5C2E3F7342E7Q34076940-74C949BC-4382-45F2-905C-2BE8CC412772Q34082672-0F864E1A-7570-4153-B038-9C600886142DQ34225567-24172D4C-29F3-4D3C-B3AF-87B975CF8606Q34254100-EE0AF2DE-BF5C-4CF5-88AA-AF912C4262E3Q34532370-6BB9F329-3CFD-4C97-B7E7-2FB7DF05805AQ34601537-7343669F-51A2-4BF2-A47A-AB9A5E2674EFQ34609654-92180193-2A8E-4AB8-8259-EB87A2D5C465Q34613494-12295671-F48F-48AE-9659-64EEB5B35960Q34627655-60BBB382-A7D3-48F4-BF90-613386C1B5D2Q34629086-D20D9CF2-FAC0-4F8A-BB8C-09B220304D20Q34668548-C0695C8B-DCA4-4636-8CED-59A1E9AF3A01Q35488811-4DE0A996-7B28-4002-BCF5-69B78AB74D16Q35875268-A1256BB1-691D-43DB-B9AB-8FF97ED2148FQ35886960-ADAD2662-DAF3-4E72-BC02-2E1516B05E11Q35913905-61F6F898-A491-417C-906C-61939C892018Q35914342-CB410D71-0DDA-4C38-92F6-BAC975C1EFFDQ36079854-0F6E1C4A-230A-46FA-AFF5-8AAB857EE298Q36278808-46019E62-BDB9-4889-9FD8-6FC2754015D5Q36292549-40885581-900F-43A9-AAF8-F25B9F0145A9Q36333204-C17D1A35-0495-4CAE-B791-DD4B5B34C75DQ36349979-B1D16AE1-E7E7-4EBA-B963-4A9CD7468C67Q36357106-F696660B-CC0C-493F-AD1D-363A971A5613Q36376082-D713A25B-85B4-4004-A46A-C37DE20BA438Q36406027-845A16EF-22B4-4F55-AD35-4B1FC0514C4DQ36481549-7EB0D1C4-0EB4-4E79-9F0A-9B35F73B8679Q36590540-42FB0B53-2ADA-4A29-B2C8-D0B59402F381Q36600329-65DDD228-4FB3-46D8-A354-D36D62E2BCBEQ36687455-4743E17D-E489-42EC-AA5F-55637F6D8BB8Q36802798-348ABBF7-25E5-4C35-A553-D46D10B4B2D9Q36803192-638C798C-4F8F-44BC-9CF0-4B9FD416D526
P2860
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年学术文章
@wuu
1980年学术文章
@zh-cn
1980年学术文章
@zh-hans
1980年学术文章
@zh-my
1980年学术文章
@zh-sg
1980年學術文章
@yue
1980年學術文章
@zh
1980年學術文章
@zh-hant
name
Monoclonal antibody against a ...... en and a neutralizing antigen.
@ast
Monoclonal antibody against a ...... en and a neutralizing antigen.
@en
type
label
Monoclonal antibody against a ...... en and a neutralizing antigen.
@ast
Monoclonal antibody against a ...... en and a neutralizing antigen.
@en
prefLabel
Monoclonal antibody against a ...... en and a neutralizing antigen.
@ast
Monoclonal antibody against a ...... en and a neutralizing antigen.
@en
P2093
P2860
P356
P1476
Monoclonal antibody against a ...... en and a neutralizing antigen.
@en
P2093
Hayward SD
Hoffman GJ
Lazarowitz SG
P2860
P304
P356
10.1073/PNAS.77.5.2979
P407
P4510
P577
1980-05-01T00:00:00Z